CANADA OPHTHALMIC DRUGS MARKET FORECAST 2023-2030

Significant progress has been witnessed in the Canadian ophthalmology industry regarding treatment options for various eye conditions. This progress includes advancements in innovative ophthalmic drugs, gene therapies, cell-based therapies, and sophisticated surgical techniques like laser vision correction and cataract surgery with premium intraocular lenses.

The Canada ophthalmic drugs market segmentation includes dosage form, therapeutic class, type, indication, and distribution channel. The indication segment includes dry eye, retinal disorder, infection/inflammation/allergies, glaucoma, and other indications.

Glaucoma comprises a group of eye diseases that harm the optic nerve connecting the eye to the brain. The condition is characterized by the progressive and irreversible loss of vision due to the gradual depletion of nerve tissue. While elevated intraocular pressure (IOP) is often linked to optic nerve damage, glaucoma can also manifest with normal or low IOP. Without intervention, glaucoma may result in permanent vision loss and blindness, making it a leading global cause of blindness. Early detection and treatment play a vital role in preserving vision.

There are various types of glaucoma, with open-angle glaucoma and angle-closure glaucoma being the two most common forms. Open-angle glaucoma, the prevailing type, occurs when the drainage angle in the eye is open, but the trabecular meshwork, responsible for draining the aqueous humor, becomes less efficient over time. This gradual inefficiency leads to an increase in intraocular pressure, ultimately causing damage to the optic nerve. Conversely, angle-closure glaucoma, while less common, is considered a medical emergency. It arises when the drainage angle in the eye becomes blocked, impeding the exit of aqueous humor and resulting in a sudden surge in IOP. If not promptly addressed, angle-closure glaucoma can lead to rapid and severe vision loss.

Dry eye, also referred to as dry eye syndrome or keratoconjunctivitis sicca, is a prevalent ocular condition resulting from insufficient tear production or rapid tear evaporation. Tears play a vital role in preserving the ocular surface’s health by supplying lubrication and safeguarding against infections. The discomfort and visual disturbances caused by dry eyes can lead to corneal and other ocular damage if untreated. Although this condition can affect individuals of all ages, its frequency tends to rise with advancing age.

Various factors contribute to the onset of dry eyes. With aging, there is typically a reduction in tear production, rendering older adults more prone to experiencing dry eye symptoms. Certain medical conditions, such as Sjögren’s syndrome, rheumatoid arthritis, diabetes, thyroid disorders, and lupus, have associations with dry eye. Moreover, specific medications, including antihistamines, decongestants, antidepressants, and certain blood pressure medications, can diminish tear production.

Some of the key firms operating in the Canada ophthalmic drugs market are Johnson & Johnson, Bausch Health Companies Inc, Pfizer Inc, etc.

Formerly recognized as Valeant Pharmaceuticals until May 2018, Bausch Health Companies Inc is a specialized pharmaceutical firm in Canada. Engaged in the development, manufacturing, and marketing of a diverse array of pharmaceutical products, the company encompasses both branded and generic pharmaceuticals, as well as over-the-counter (OTC) items. The extensive product portfolio spans gastrointestinal and dermatology products, aesthetics devices, international pharmaceuticals, generics, neurology, dentistry, and vision care.

Bausch Health operates through five distinct segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. It is headquartered in Laval, Canada.